Business Description
Alterity Therapeutics Limited is a Melbourne-based medical research company focused on developing treatments for serious brain diseases, including Parkinson's disease and Multiple System Atrophy. Its main drug candidate, ATH434, is currently being tested in multiple Phase II clinical trials across both conditions. The company also runs a drug discovery program that produces new chemical compounds aimed at treating the root causes of neurological diseases. Originally founded in 1997 as Prana Biotechnology Limited, the company adopted its current name in 2019.
